1. Introduction {#s0005}
===============

Each year, \> 500,000 people die from lung adenocarcinoma (LUAD) globally, and only a minority of these tumors harbor alterations targetable by existing personalized therapies ([@bb0090], [@bb0050]). Research into targeting new oncogenes is crucial to expanding the proportion of treatable tumors. The genomic locus containing the adenosine deaminase acting on RNA (*ADAR*) gene is amplified in 13% of LUAD and has been functionally confirmed as an oncogene in lung ([@bb0005]), breast ([@bb0055]), stomach ([@bb0030]), chronic myeloid leukemia ([@bb0095]) and liver ([@bb0040]) cancers. Knockdown of *ADAR* in LUAD is associated with reduced in-vitro cell viability, and decreased metastatic potential in xenograft mouse models ([@bb0005]). Therefore, targeted therapies towards and a greater functional understanding of *ADAR* amplified tumors have the potential to greatly increase the number of treatable cases of LUAD.

Adenosine to inosine RNA editing is mediated predominantly by the *ADAR* gene and to a lesser extent, the *ADARB1* gene. This modification occurs in millions of sites across the transcriptome, mostly within Alu repeats ([@bb0015]). Previous studies of the oncogenic role of *ADAR* in cancer have focused on the editing of coding sequences of tumor-associated proteins, such as *AZIN1* ([@bb0040]) and *NEIL1* ([@bb0005]). Although this role has been confirmed in functional studies of hepatocellular carcinoma, \< 1% of known RNA editing sites reside in coding sequences ([@bb0080]). The function of RNA editing in non-protein coding regions is only known for a few edited genes. For example, it has been shown that *ADAR*-mediated RNA editing changes the accessibility to the HuR RNA binding protein (RBP) within the cathepsin S (*CTSS*) 3′ UTR, which enhances its mRNA\'s stability in endothelial cells ([@bb0185]). In addition, Zhang et al. showed that RNA editing of the *MDM2* 3′ UTR segment can abolish mir-200b mediated repression of the *MDM2* mRNA. Recently, RNA editing of non-coding regions by *ADAR* has been implicated in immune regulation ([@bb0130], [@bb0125], [@bb0165], [@bb0065]) and apoptosis ([@bb0220], [@bb0180]), but it is not clear how these functions are related to *ADAR*\'s oncogenic potential.

Here, we investigate the role of mRNA abundance regulation by RNA editing in human LUAD. We create a pipeline that inputs RNA gene abundances and RNA editing frequencies, and outputs potentially regulatory pairs of RNA editing sites and mRNA target genes. This pipeline is applied to The Cancer Genome Atlas (TCGA) LUAD RNA sequencing data to obtain a global picture of the RNA regulatory editome. We identify enrichment of both apoptosis and immunoregulatory genes potentially regulated by *ADAR*-mediated RNA editing. *ADAR* is alternatively spliced into two separate isoforms: a short, nuclear, and constitutively expressed p110 isoform; and a long, cytosplasmic, and interferon inducible p150 isoform ([@bb0165]). The p110 isoform is responsible for fine tuning apoptosis, at least in part via modulating accessibility to Staufen 1 binding sites in edited mRNA\'s ([@bb0220], [@bb0180]). The p150 isoform edits double stranded dsRNA\'s and prevents them from activating the MDA5-MAVS interferon response. Neither of these functions of *ADAR* have been linked to cancer, although it was seen by Fumagalli, et al. that *ADAR* RNA expression is jointly explained by *ADAR* genomic copy number and *STAT1* expression, a marker of interferon activity ([@bb0055]). We further establish that *ADAR* genomic copy number (CN) is negatively associated with immune and apoptosis pathways, as well as immune cell signatures, establishing potential oncogenic roles for *ADAR* in LUAD.

2. Materials and Methods {#s0010}
========================

2.1. Data {#s0015}
---------

RNAseq abundances, copy number data, and editing frequencies were downloaded for lung adenocarcinoma (LUAD) matched normal and tumor samples. RNAseq gene level expression (RNAseqV2 RSEM) and copy number data were downloaded from Broad Institute Firehose (<https://gdac.broadinstitute.org>). Gistic 2.0 copy number data was further processed to gene level as follows. If a gene is contained within a segment as defined in the gistic-processed data, the value of that segment is assigned to the gene. Editing frequency data was downloaded from [synapse.org](http://synapse.org){#ir0010} ([https://www.synapse.org/\#!Synapse:syn2374375/files/](https://www.synapse.org/#!Synapse:syn2374375/files){#ir0015}) ([@bb0080]). Editing frequency is the number of edited reads covering a given editing site divided by the total number of reads covering that editing site. Editing sites are annotated in the RADAR ([@bb0170]) database, which collects and curates functionally validated A-I RNA editing sites.

2.2. Identification of Regulatory Edits {#s0020}
---------------------------------------

First, RNA editing sites were matched to the genes containing them. Often, there are multiple RNA editing sites within each gene. Then, for each gene, RNA editing frequencies were associated to RNA abundances with spearman correlation. Significant edits were determined using R\'s (v1.0.136) built in significance of correlation test and corrected for multiple hypothesis testing (Benjamini Hochberg corrected q-value \< 0.1). All correlations performed in this study are spearman correlations.

2.3. RNA Binding Protein and microRNA Motif Analysis and Secondary Structure Visualization {#s0025}
------------------------------------------------------------------------------------------

Regulatory edits were grouped by gene and searched for continuously edited regions (CER). A CER was defined as \> 5 sequential significant RNA regulatory editing sites, with no two consecutive RNA editing sites being separated by \> 100 base pairs. These CERs were then input as a bed file into the RBPmap tool (<http://rbpmap.technion.ac.il>) ([@bb0155]), which searches for RNA binding protein (RBP) motifs within genomic regions. We used the following parameters in our searches: high stringency, hg19 reference, all Human/Mouse motifs, and no conservation filter. MicroRNA motif enrichment was calculated using the targetScan web tool ([@bb0070]), and microRNA\'s with combined score \< − 0.3 were considered for further analysis. Secondary structure prediction was made with the Forna ([@bb0100]) web app.

2.4. Pathway and Immune Cell Analysis {#s0030}
-------------------------------------

Pathway scores for tumor samples were calculated using single sample gene set enrichment analysis (SSGSEA) ([@bb0020]). Immune exclusion and tumor purity scores were downloaded from [@bb0010] and converted to immune infiltrate scores (1-SCORE). Immune cell subset analysis was performed using the TIMER web app (<https://cistrome.shinyapps.io/timer/>) ([@bb0110]).

2.5. Histological Slide Evaluation of Immune Cell Subsets {#s0035}
---------------------------------------------------------

Histological slides for TCGA LUAD tumors, were visualized using the digital slide archive (<http://cancer.digitalslidearchive.net>) ([@bb0075]). We selected a subset of tumors such that there were roughly equal representation of *ADAR* amplified and normal copy numbers. In total, 97 LUAD tumors, 45 of which had no evidence of *ADAR* amplification, and 52 of which had high *ADAR* copy number, were selected for analysis and we conducted the experiment with no knowledge of the *ADAR* CN status of these tumors. We were able to visually estimate neutrophil, lymphocyte, and macrophage infiltrations, as well as necrosis on a scale of 0--3.

3. Results {#s0040}
==========

3.1. Pipeline for Discovery of Regulatory A-I RNA Editing Sites {#s0045}
---------------------------------------------------------------

We created a pipeline for discovery of regulatory RNA editing sites as follows. We first matched each RNA editing site with its host RNA abundance ([Fig. 1](#f0005){ref-type="fig"}A), then tested all RNA edits for their association with host RNA abundance ([Fig. 1](#f0005){ref-type="fig"}B--C). All relevant code can be found at [github.com/michaelsharpnack/RNA_edits](http://github.com/michaelsharpnack/RNA_edits){#ir0035}.Fig. 1Pipeline to discover regulatory RNA editing sites. Editing sites annotated in RADAR database are matched to their host gene (A). The regulatory potential of each editing site is discovered by testing the association between editing frequency and host RNA abundance (B). In this case, one editing site is significantly positively associated with RNA abundance (A1, maroon) and is classified as a potential regulatory editing site (C).Fig. 1

3.2. Landscape of Regulatory Editing Sites in Lung Adenocarcinoma {#s0050}
-----------------------------------------------------------------

Previous papers have focused on the potential for protein coding RNA editing sites to modify oncogene and tumor suppressor functions; however, the frequencies of many non-coding RNA editing sites are significantly increased in LUAD. In the TCGA LUAD cohort, 4115 non-protein-coding RNA editing sites were differentially edited (*t*-test, BH q-value \< 0.1) while only 20 protein coding RNA editing sites were differentially edited (Supplementary Fig. 1). We therefore applied our regulatory RNA editing pipeline to the TCGA LUAD RNAseq dataset to discover alternative functions of the *ADAR* oncogene.

RNAseq data for 488 LUAD tumor and 57 matched normal samples were run through our regulatory RNA editing pipeline. This data includes 54,362 frequently edited sites, and 52,276 RNA editing site-RNA abundance combinations tested for their regulatory potential. 5468 (10%) of the edit-gene combinations were predicted to have regulatory potential across 1413 genes ([Fig. 2](#f0010){ref-type="fig"}A). The majority of the significant RNA editing sites had a positive association with RNA abundance (4976 or 91%, [Fig. 2](#f0010){ref-type="fig"}B). It is possible that the enrichment of positive RNA editing-mRNA abundance associations is due to a bias in detection; given that we would not be able to measure frequently edited transcripts that are degraded. Gene expression and length are both potential sources of bias in regulatory RNA editing site detection. The expression of each gene with detectable RNA editing sites is, although significantly so, very weakly associated with the ability to detect regulatory RNA editing sites (ρ = 0.059, *p* = 5 × 10^− 4^). Gene length and the number of Alu elements within each gene are also not strongly associated with the number of detected regulatory RNA editing sites (ρ = − 0.066, *p* = 1 × 10^− 4^ for total gene length; and ρ = 0.028, *p* = 0.10 for the number of Alu elements present in the gene body).Fig. 2Landscape of regulatory RNA editing sites in LUAD. (A) Plot showing the distribution of RNA editing site-mRNA abundance correlation and the significance of the association. The red line denotes q-value \< 0.1 significance threshold. Histogram of regulatory RNA editing sites\' association to RNA abundance (B). Genes are ranked by the number of predicted regulatory RNA editing sites within their RNA molecule, and the top 50 are shown in (C). Edits are grouped by their host gene and RNA editing site-RNA spearman correlations are compared between tumor and normal (D). Genes with high Tumor-normal regulatory RNA editing site correlation have regulatory RNA editing sites with similar regulatory potential in both tumor and normal. The tumor-normal edit correlation is plotted against the number of regulatory edits in each host RNA molecule (E).Fig. 2

293 of the genes tested (8.5%) had \> 5 predicted regulatory RNA editing sites, and the genes with the top 50 RNA editing sites are shown in [Fig. 2](#f0010){ref-type="fig"}C. Regulatory relationships between ADAR and these genes have only been investigated for a small number of these genes, including *CTSS* ([@bb0185]) and *MDM2* ([@bb0225]). Remarkably our method was able to discover these established regulatory relationships. CTSS is the best-studied example of gene regulation by *ADAR*, and *CTSS* is the top hit according to our algorithm. For a full list of genes with predicted regulatory RNA editing sites, please see [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}. In addition, we investigated for possible enrichment of putative regulatory relationships that are evolutionarily conserved. 1664/11319 (14.7%) and 4475/40957 (10.9%) of RNA editing sites were significant in rhesus or chimp and non-conserved, respectively, indicating an enrichment of regulatory RNA editing sites in evolutionarily conserved RNA editing sites (fisher\'s exact test, *p* \< 2.2e^− 16^).

We next sought to discover which regulatory relationships are present in both tumor and normal, and which are only present in tumor. Since there are so many fewer normal samples, instead of comparing statistical significance of RNA editing sites between tumor and normal, we compared the spearman correlations. For each gene, we calculated the spearman correlation between the tumor and normal regulatory correlations of all the RNA editing sites within that gene. A high tumor-normal correlation indicates that RNA editing mediated regulation of a gene is not cancer specific. Of the 344 genes with at least 5 regulatory RNA editing sites in tumors, 54/344 (16%) of these genes\' edits had a positive correlation between tumor and normal regulatory RNA editing sites of ρ \> 0.3, while 16 had a negative correlation of ρ \< − 0.3. 274/344 (80%) of the regulatory edits are cancer-specific, especially in the genes with the highest numbers of RNA editing sites ([Fig. 2](#f0010){ref-type="fig"}E).

The *ADAR* gene regulates the majority of RNA editing sites, while the *ADARB1* gene regulates a relatively small portion (Supplementary Fig. 2). Because *ADAR* and *ADARB1* are upregulated and downregulated in LUAD (Supplementary Fig. 3), respectively, the majority of RNA editing sites is over-edited in tumors (Supplementary Fig. 1B). There are 756 differentially edited regulatory RNA editing sites across 242 differentially expressed genes. Given that the majority of regulatory RNA editing sites are positively associated with target RNA expression, one would expect to see that over-edited genes also tend to be overexpressed. In fact, 558/756 (74%) of the regulatory RNA editing sites are over-edited while their host genes are overexpressed, and 93% of these RNA editing sites are positively associated with RNA abundances in tumors. Of the remaining RNA editing sites, 137/756 (18%) are over-edited with host genes that are underexpressed. Unsurprisingly, 41% of these editing sites are negatively associated with RNA abundances in tumors (Supplementary Fig. 4). Together, these results show that *ADAR* overexpression in tumors potentially controls cancer-specific differential expression of hundreds of genes in LUAD.

An alternative hypothesis to RNA-editing mediated mRNA abundance regulation is that mRNA abundances are merely associated with RNA editing frequencies. In particular, *ADAR* is upregulated by interferon signaling, which could also regulate genes that are edited by *ADAR*. To isolate the effects of *ADAR* on its target genes, we compared the results from *ADAR* knockdown experiments on human B-Cells from [@bb0205] to our results in human LUAD. Interferon pathways were not significantly enriched among differentially expressed genes after *ADAR* knockdown in their study. Wang et al. found 105 genes with evidence of RNA editing had both alterations in RNA editing frequency and mRNA abundance after *ADAR* knockdown via siRNA. 84/105 (80%) of these genes also displayed evidence of editing in the TCGA LUAD dataset, and 54/84 (64%) of the genes found to be regulated by RNA editing were also putative regulated genes found by our method, representing a significant enrichment. We performed a permutation test to assess the significance of this result by selecting 10^5^ random subsets of 1413 genes from the 3412 genes with evidence of editing. In none of these iterations did a random gene set have a \> 64% overlap with the set from Wang et al., a probability of \< 1 × 10^5^ that the overlap in our results and the results of Wang et al. occurred randomly. For example, *APOL1*, *CFLAR*, *DAP3*, *EIF2AK2*, and *MAVS* were all putative regulated genes found by both our method and Wang et al. For a full comparison, see [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}.

3.3. The *APOL1* 3′ UTR Contains Multiple Cancer-specific Regulatory Editing Sites Controlled by *ADAR* {#s0055}
-------------------------------------------------------------------------------------------------------

The *CTSS* and Apolipoprotein L1 (*APOL1*) genes had the largest number of predicted regulatory editing sites in LUAD ([Fig. 2](#f0010){ref-type="fig"}C). Since an *ADAR*-*CTSS* regulatory relationship has already been established, we investigated the RNA editing patterns within the 3′ UTR of the *APOL1* gene. *APOL1* functions are not well characterized; however, it circulates with the densest HDL subfraction, HDL3 ([@bb0140]). *APOL1* variants have been implicated in chronic kidney disease ([@bb0150]), and they likely evolved due to their protective effects against *T. brucei rhodesiense* infections ([@bb0195]). *APOL1* is upregulated after interferon treatment or *TLR3* stimulation via an *IRF3*-dependent pathway, and high *APOL1* expression in HIV-infected patients with an interferon response contributes to chronic kidney disease ([@bb0145]). Despite its role in innate immunity and status as an interferon-regulated gene, *APOL1* has not yet been associated to *ADAR*-mediated regulation.

*APOL1* editing sites are frequently edited---21/74 (28%) sites have \> 10% average editing frequency across all patients in LUAD ([Fig. 3](#f0015){ref-type="fig"}A). 71/74 (96%) editing sites in the *APOL1* 3′ UTR that are consistently edited in LUAD have predicted regulatory roles, and editing of these sites is positively associated with *APOL1* RNA abundance ([Fig. 3](#f0015){ref-type="fig"}B). To test whether *ADAR* or *ADARB1* controls the editing of *APOL1*, the editing frequencies of the predicted regulatory sites were correlated with the RNA abundances of *ADAR* and *ADARB1*, respectively. The editing frequency of the majority of these sites as well as *APOL1* RNA abundance was significantly correlated with *ADAR* RNA abundance, indicating that *ADAR*, not *ADARB1*, controls them ([Fig. 3](#f0015){ref-type="fig"}C--D). In addition, [@bb0205] found that after siRNA knockdown of *ADAR*, both *APOL1* editing and gene expression decreased ([Supplementary Table 2](#ec0010){ref-type="supplementary-material"}).

We next sought to discover if the regulation of *APOL1* could be cancer related. *APOL1* is overexpressed in LUAD compared to matched normal tissue samples (q \< 0.1), and 26/74 (35%) of its RNA editing sites show increased evidence of editing in cancer. In tumors where *APOL1* is over-edited, it also tends to be overexpressed ([Fig. 3](#f0015){ref-type="fig"}E). Together, this evidence suggests that *ADAR* overexpression and associated increased editing in LUAD potentially induces overexpression of *APOL1*.Fig. 3The *APOL1* 3′ UTR contains multiple regulatory editing sites controlled by *ADAR*. *APOL1* 3′ UTR contains several RNA editing sites which are edited at a very high frequency (A), and most are significantly positively correlated to *APOL1* mRNA abundance (B). *APOL1* editing frequencies (C) and RNA abundances (D) are both positively correlated with *ADAR* RNA abundance. [Fig. 3](#f0015){ref-type="fig"}E shows for each patient the difference in chr22:36,662,382 editing frequency and *APOL1* mRNA abundance between tumor and normal. *APOL1* tends to be over-edited and overexpressed in the same tumors (Rho = 0.27, *p* = 0.056). \*q \< 0.1.Fig. 3

Since our method provides nucleotide level regulatory hypotheses, we performed a secondary structure analysis on the edited regions of the *APOL1* 3′ UTR. We discovered that many of the regulatory RNA editing sites change the predicted secondary structure, and several of these regulatory RNA editing sites potentially effect RBP and microRNA motifs, including numerous predicted *PTBP1* binding sites (Supplementary Figs. 5--6). *PTBP1* is overexpressed in tumors and correlated with *ADAR* expression (Supplementary Fig. 7). However, the predictions of RNA secondary structure, and RBP and microRNA motifs are not perfect and require functional validation.

3.4. RNA Editing of the *APOL1* 3′ UTR is Associated With Poor Overall Survival in Lung Adenocarcinoma {#s0060}
------------------------------------------------------------------------------------------------------

We next investigated the clinical importance of *APOL1* in LUAD. We separated the tumors into *APOL1* high and *APOL1* low based on the mean *APOL1* expression across all tumors and performed survival analysis ([Fig. 4](#f0020){ref-type="fig"}A). High *APOL1* expression is significantly associated with poor prognosis (chi-square, *p* = 0.0066). In addition, high *APOL1* expression is associated with poor survival using the survival meta-analysis tool, precog ([precog.stanford.edu](http://precog.stanford.edu){#ir0040}) ([@bb0060]), which compiles the results of several gene expression datasets in lung adenocarcinoma (z = 3.37, p \< 10^− 3^). To determine if this effect was due to RNA editing or other modes of *APOL1* regulation, we then repeated this survival analysis across all 74 editing sites in the *APOL1* 3′ UTR. 30/74 (41%) of the RNA editing sites within the 3′ UTR of *APOL1* are significantly associated with poor prognosis in LUAD (chi-square, q-value \< 0.1). The most significant edit (q = 0.020) was also the closest to the *APOL1* coding region, located at chr22:36662161 ([Fig. 4](#f0020){ref-type="fig"}B). Editing of this site is predicted to remove a kink in the secondary structure of the *APOL1* 3′ UTR (Site 20 in Supplementary Fig. 5A--B). An alternative hypothesis is that overall editing rates are prognostic, and not just specific sites; however, [@bb0160] investigated this hypothesis and did not report a significant association between global editing rates and overall survival in LUAD.Fig. 4Survival analysis of *APOL1* RNA expression and *APOL1* editing sites. Tumors are separated into low vs. high *APOL1* expression based on mean expression (A). Tumors are separated into low vs. high chr22:36662161 editing frequency (B). *P*-values are calculated from Chi-Square tests.Fig. 4

3.5. *ADAR* Regulated Genes Come From Apoptosis and Innate Immune Related Pathways {#s0065}
----------------------------------------------------------------------------------

We performed functional enrichment ([enrichr.org](http://enrichr.org){#ir0045}) ([@bb0035], [@bb0105]) of the genes with five or more regulatory RNA editing sites in LUAD and found enrichment of apoptosis related genes ([Fig. 5](#f0025){ref-type="fig"}A). In particular, we found that *DFFA*, *CASP6*, *CASP8*, *CASP10*, *MDM2*, and *CFLAR* all contain multiple predicted regulatory RNA editing sites (shown in parentheses). These genes are inhibitors of the FAS ligand induced apoptotic pathway and except for *MDM2* ([@bb0225]), have not yet been linked to *ADAR*-mediated regulation ([Fig. 5](#f0025){ref-type="fig"}B).Fig. 5RNA-editing regulated genes in LUAD are enriched in apoptosis and innate immune-related genes. Biocarta pathway enrichments of genes with 5 or more predicted regulatory RNA editing sites (A). Pathway diagram showing the genes that are enriched in the apoptosis (B) and innate immune-related pathways (C). Blue and red colored proteins indicate positive and negative regulation by *ADAR*-mediated RNA editing, respectively. The MAVS protein is colored in both blue and red because there are both positive and negative regulatory edits within its 3′ UTR.Fig. 5

In addition, we found enrichment of 2 pathways related to the innate immune functions of *ADAR* (significant by *p*-value but not after multiple hypothesis correction). Most importantly, *EIF2AK2* (PKR), *EIF2S3* (EIF2γ), *DDX58* (RIG-I) and *MAVS* contain numerous regulatory edits ([Fig. 2](#f0010){ref-type="fig"}). These proteins are all interferon stimulated, and act in concert to inhibit the replication of dsRNA viruses. PKR phosphorylates EIF2α and leads to inhibition of the EIF2 complex, of which EIF2γ is the core subunit ([@bb0025]) ([Fig. 5](#f0025){ref-type="fig"}C). Inhibition of the EIF2 complex halts translation and leads to stress granule responses ([@bb0135]). Our results predict that *ADAR* positively regulates these genes via editing of their 3′ UTR\'s. In addition, Li Y., et al. noted that *ADAR* knockdown in interferon stimulated human LUAD A549 cells prevented the expected upregulation of *EIF2AK2*, suggesting that *ADAR* is necessary for interferon-mediated *EIF2AK2* expression. The authors were unable to explain this finding; however, our method predicts that *ADAR* upregulates *EIF2AK2* via editing of its 3′ UTR ([@bb0115]).

Interlinked with stress granule formation in the innate immune response to dsRNA, is the MDA5-MAVS complex. MDA5 binds to unedited dsRNA molecules and is the first step of the dsRNA antiviral interferon response ([@bb0215]). The MAVS protein binds to MDA5 and forms filaments on the mitochondrial membrane and acts as an adaptor in this process ([@bb0085]). *MAVS* contains both positive and negative regulatory RNA editing sites in LUAD. In fact, RNA editing sites within the *MAVS* 3′ UTR that have higher mean editing frequency tend to be more negatively associated with *MAVS* abundance (Rho = − 0.57, *p* = 6.6 × 10^− 11^, Supplementary Fig. 8A). This suggests that there is a more complex regulatory process governing *MAVS* RNA abundance. This pattern is present in other RNA molecules with multiple negative regulatory sites, such as *LIMD1* and *VHL* (Supplementary Fig. 8B---C).

It is important to note that the same bias that has caused enrichment in positive regulation by RNA editing in a majority of regulatory RNA editing sites may also bias the pathway enrichment analysis we performed. In addition, we performed an analysis to uncouple the upstream effects of interferon pathway expression on potential regulatory RNA editing sites. We split patients into four groups based on interferon pathway expression and RNA editing levels at each RNA editing site, and then compared the gene expression for genes with potential regulatory RNA editing sites between these groups. We tested 6139 regulatory RNA editing sites for potential regulation by RNA editing independent of interferon pathway expression. 2494 regulatory RNA editing sites were measured in a sufficient number of tumors (*N* \> 200) for comparison, and we found evidence of widespread regulation of their host genes by RNA editing independent of interferon pathway expression (full data available in [Supplementary Table 3](#ec0015){ref-type="supplementary-material"}). In addition, there are numerous genes whose expression is both independently associated with RNA editing levels and interferon levels. For example, EIF2AK2 is highly expressed in tumors with high 3′ UTR RNA editing and high interferon pathway expression; moderately expressed in tumors with either high 3′ UTR RNA editing or high interferon pathway expression; and lowly expressed in tumors with low 3′ UTR RNA editing and low interferon pathway expression (Supplementary Fig. 9). This result is consistent with the finding by Li et al. that both *ADAR* and interferon expression are necessary to induce *EIF2AK2* expression ([@bb0115]).

3.6. *ADAR* Copy Number is Anti-correlated With Immune and Apoptotic Signatures in Lung Adenocarcinoma {#s0070}
------------------------------------------------------------------------------------------------------

To investigate the role of *ADAR* in immune and apoptotic pathways we calculated the pathway enrichment in each tumor sample using single sample gene set enrichment analysis (ssGSEA) ([@bb0020]) on the 50 MSigDB hallmark gene sets ([@bb0120]). *ADAR* was initially identified as an oncogene due to its frequent amplification in several human cancers ([@bb0080]). As such, we investigated the association between *ADAR* CN and pathway activity, and found that for many pathways, the association between *ADAR* CN and pathway activity is the opposite of the association between *ADAR* RNA abundance and pathway activity, in spite of a high *ADAR* CN-RNA correlation (ρ = 0.50). We found that *ADAR* CN is strongly negatively associated with apoptotic activity in LUAD ([Fig. 6](#f0030){ref-type="fig"}A). *ADAR* RNA abundance was not correlated with the apoptosis pathway in LUAD. Similarly for immune related measures, *ADAR* RNA is positively correlated with the interferon alpha pathway but *ADAR* CN is negatively associated with it ([Fig. 6](#f0030){ref-type="fig"}A). One possible explanation for this finding is that separate *ADAR* isoforms have opposing effects on immune and apoptotic pathways. The *ADAR* p150 isoform contains exon 1 while *ADAR* p110 does not; however, the exons are too highly correlated to distinguish between their expression. The lowest correlation between exon 1 and exons 2--15 expression is 0.77. Therefore, we cannot distinguish between the expression of *ADAR* p150 or *ADAR* p110 in this cohort.Fig. 6*ADAR* amplification is associated with decreased immune cell concentrations in lung adenocarcinoma. [Fig. 6](#f0030){ref-type="fig"}A shows the correlation between *ADAR* RNA and CN abundances and relevant pathway, tumor purity, and immune infiltrate signatures. The TIMER app was used to estimate immune cell subtype concentrations in LUAD tumors with known *ADAR* CN status (B). Tumors with *ADAR* CN gain or amplification had evidence of significantly fewer CD8 + T Cells, CD4 + T Cells, Macrophages, Neutrophils, and Dendritic Cells. Histological slides were scored for their lymphocyte concentrations on a grade 0--3 (C). Significance codes for (B): 0 ≤ \*\*\* ≤ 0.001 ≤ \*\* ≤ 0.01 ≤ \* ≤ 0.05.Fig. 6

Given the finding that *ADAR* CN is negatively associated with signatures of apoptosis and innate immunity, we investigated the association between *ADAR* CN and immune infiltrates. We first downloaded tumor purity and immune infiltrate data from [@bb0010] and then used the TIMER app (<https://cistrome.shinyapps.io/timer/>) (Li[@bb0110]) to test for associations with specific immune cell types. We found that *ADAR* CN is significantly negatively associated with all markers of immune infiltrate and tumor purity used in Aran et al. ([Fig. 6](#f0030){ref-type="fig"}A). In fact, given the strength of the association, we searched the entire genome for genes whose copy numbers negatively correlate with immune infiltrate signatures in LUAD. It was found that genes most negatively associated with immune infiltrates reside on the 1q21 locus (Supplementary Figs. 10--11), and form a coherent amplicon that includes *ADAR* (Supplementary Fig. 11B). We further discovered that *ADAR* genomic gains and amplifications have significantly fewer predicted concentrations of CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and dendritic cells ([Fig. 6](#f0030){ref-type="fig"}B). It is possible that other genes located at the 1q21 locus mediate this effect, and the causal role of *ADAR* in immune exclusion requires functional validation.

To confirm this finding, we graded LUAD tumors based on their apparent infiltration of different immune cell types on a 0--3 scale in histological slides from TCGA (<http://cancer.digitalslidearchive.net>) ([@bb0075]). We selected 97 LUAD tumors, 45 of which had no evidence of ADAR amplification, and 52 of which had high *ADAR* copy number, and conducted the experiment with no knowledge of the *ADAR* CN status of these tumors. We were able to visually estimate neutrophil, lymphocyte, and macrophage infiltrations, as well as necrosis. While no apparent pattern was observed for neutrophils, necrosis, and macrophages, there was a trend towards fewer lymphocytes in *ADAR* CN high tumors (*t*-test, *p* = 0.01) ([Fig. 6](#f0030){ref-type="fig"}C).

The fundamental question is, does RNA abundance regulation by RNA editing account for the differences between *ADAR* RNA and copy number pathway enrichments? We looked at the independent effects of interferon pathway expression and *ADAR* copy number on editing levels, by doing a differential editing experiment with one of the variables controlled. The differences in editing between copy number high vs. low and interferon high vs. low are extremely similar (ρ = 0.76). In other words, whether *ADAR* is upregulated by interferon or copy number amplifications doesn\'t matter, the same RNA editing sites are changed. This is evidence against RNA abundance regulation by RNA editing as being the driving force behind the intransitive relationship that we see between *ADAR* RNA, copy number, and interferon expression.

4. Discussion {#s0075}
=============

Despite the prevalence of A-I RNA editing of non-coding regions within mRNAs, very little research has been done to elucidate the functions of these alterations in cancer. To remedy this situation, we perform a comprehensive analysis of RNA abundance regulation by RNA editing. These results are a resource to better understand the regulation of thousands of genes, and a full list of genes with regulatory edits is provided in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}. Despite confirmation of some of these results in an ADAR knockdown experiment, further functional validation is necessary to confirm the causality of these regulatory relationships. This method can be run on any dataset of matched RNA abundance and RNA editing frequencies, and it provides nucleotide level information to better guide validation experiments. For example, our method could be used as a resource to understand the RNA regulatory landscape of normal tissues from data published by ([@bb0190]). A limitation of our method is a lesser ability to detect negative compared to positive regulatory relationships. Detection of negative relationships may require time-lapse functional experiments, where the degradation of heavily edited transcripts can be tracked in real time.

In addition, an integrative analysis of *ADAR* CN and pathway enrichments showed that despite the high correlation between *ADAR* CN and RNA, *ADAR* copy number and RNA tend to have opposite relationships with immune and apoptosis pathways. *ADAR* is an interferon stimulated gene ([@bb0165]), and positive correlation between *ADAR* RNA and immune regulated pathways could point towards *ADAR* being upregulated in a compensatory fashion by interferon stimulation. Sensing of aberrant DNA or RNA, such as by toll like receptors and *MDA5* can cause this interferon stimulation. When *ADAR* is genomically amplified, these patterns could imply that unregulated increases in *ADAR* expression constitutively repress interferon in the tumor microenvironment and drive tumor immune evasion. It has been shown previously that poly(I:U) dsRNA is sufficient to decrease interferon responses ([@bb0200]). In addition, this finding raises the possibility of a synergism between *ADAR* inhibition and immunotherapies. Three studies recently discovered that DNA methylation inhibitors induce an interferon response via expression of aberrant dsRNA\'s, and can even induce sensitivity to immune checkpoint therapies ([@bb0045], [@bb0175], [@bb0210]). In a similar manner, *ADAR* inhibition could be a new addition to combination immunotherapies.
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